In patients with adult respiratory distress syndrome (ARDS), inhaled nitric oxide (NO) may both reduce pulmonary hypertension and improve arterial oxygenation [1, 2] . The NO-induced decrease in pulmonary artery pressure depends on the selective pulmonary vasodilating effect of inhaled NO [3] , while the NO-induced increase in arterial oxygenation is related to the redistribution of pulmonary blood flow to well-ventilated lung areas, which results in improved ventilation to perfusion matching [1, 4] . Although potentially beneficial, inhaled NO is a toxic compound, and its toxicity is increased by the oxidation of NO to NO 2 , which occurs during administration of inhaled NO, especially when the inhaled oxygen concentration is high [5] . In order to minimize the risks of toxicity, inhaled NO should be administered at the lowest effective concentration to achieve maximal therapeutic effects [6, 7] .
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In patients with adult respiratory distress syndrome (ARDS), inhaled nitric oxide (NO) may both reduce pulmonary hypertension and improve arterial oxygenation [1, 2] . The NO-induced decrease in pulmonary artery pressure depends on the selective pulmonary vasodilating effect of inhaled NO [3] , while the NO-induced increase in arterial oxygenation is related to the redistribution of pulmonary blood flow to well-ventilated lung areas, which results in improved ventilation to perfusion matching [1, 4] . Although potentially beneficial, inhaled NO is a toxic compound, and its toxicity is increased by the oxidation of NO to NO 2 , which occurs during administration of inhaled NO, especially when the inhaled oxygen concentration is high [5] . In order to minimize the risks of toxicity, inhaled NO should be administered at the lowest effective concentration to achieve maximal therapeutic effects [6, 7] .
There is conflicting information on the NO dose for optimal treatment of pulmonary hypertension and hypoxaemia in ARDS. It has been shown that very low NO doses (<1 parts per million (ppm)) may have a measurable effect both on pulmonary circulation and on arterial oxygenation in ARDS patients [8] [9] [10] . Published data indicate that low NO doses, between 1-5 ppm, achieve maximal haemodynamic and oxygenation responses [9] [10] [11] [12] . However, other studies in ARDS patients indicate that higher NO doses may induce an additional reduction in pulmonary hypertension and hypoxaemia. In a study by GERLACH et al. [13] , a dose of NO as high as 100 ppm was required to achieve maximal pulmonary vasodilation, while the impro-vement in arterial oxygen tension (Pa,O 2 ) was maximal at 1 ppm. In contrast, a study on septic ARDS patients rep-orted a dose-dependent increase in Pa,O 2 in the range 0.1-150 ppm and a plateau effect in pulmonary pressure at 5 ppm [14] . A recent study showed that the optimum NO dose to improve Pa,O 2 may vary widely between individuals, ranging 0.1-100 ppm [15] . In that same study, however, the effect on pulmonary haemodynamics was negligible.
The aim of this study was to evaluate the dose-response effect of inhaled NO (0.5-100 ppm) on gas exchange and haemodynamics in ARDS patients treated with conventional mechanical ventilation.
Materials and methods

Patients
During a 10-month period, 19 consecutive patients who were mechanically ventilated for severe ARDS were screen- Of 19 consecutive ARDS patients on mechanical ventilation, eight (42%) responded to a test of 10 parts per million (ppm) NO inhalation with a 25% increase in arterial oxygen tension (Pa,O 2 ) over the baseline value. The eight NO-responders were extensively studied during administration of seven inhaled NO doses: 0.5, 1, 5, 10, 20, 50 and 100 ppm.
Pulmonary pressure and pulmonary vascular resistance exhibited a dose-dependent decrease at NO doses of 0.5-5 ppm, with a plateau at higher doses. At all doses, inhaled NO improved O 2 exchange via a reduction in venous admixture. On average, the increase in Pa,O 2 was maximal at 5 ppm NO. Some patients, however, exhibited maximal improvement in Pa,O 2 at 100 ppm NO. In all patients, the increase in arterial O 2 content was maximal at 5 ppm NO. The lack of further increase in arterial O 2 content above 5 ppm partly depended on an NO-induced increase in methaemoglobin. Respiratory mechanics were not affected by NO inhalation.
In conclusion, NO doses ð5 ppm are effective for optimal treatment both of hypoxaemia and of pulmonary hypertension in adult respiratory distress syndrome. Although NO doses as high as 100 ppm may further increase arterial oxygen tension, this effect may not lead to an improvement in arterial O 2 content, due to the NOinduced increase in methaemoglobin. It is important to consider the effect of NO not only on arterial oxygen tension, but also on arterial O 2 content for correct management of inhaled nitric oxide therapy. Eur Respir J 1998; 12: 1164 -1171 ed for inclusion into the study. Diagnosis of ARDS was performed in accordance with the definitions of the American-European consensus conference [16] . Inclusion criteria were early and acute onset of ARDS, lung injury severity score [17] Š2.5 and a positive test to inhaled NO at a concentration of 10 ppm, defined as a 25% increase in Pa,O 2 over the baseline value. Exclusion criteria were cardiovascular instability and pre-existing lung disease. Additional organ failures were determined according to the Sepsis-related Organ Failure Assessment (SOFA) score [18] . Of the 19 patients tested for inclusion in the study, 11 were excluded because of a negative test to inhaled NO. The remaining eight patients were all included in the study. The clinical data for these eight patients, recorded just before initiation of the protocol, are listed in table 1. All patients were sedated with fentanyl and haloperidol, paralysed with pancuronium bromide and ventilated with a volume-controlled ventilator (Amadeus; Hamilton Medical AG, Rhäzüns, Switzerland). Controlled mechanical ventilation was adjusted to maintain the patient's original ventilatory settings and was administered with constant minute ventilation (7.8±2.6 L·min -1 ), positive end-expiratory pressure (PEEP; 10.5±2.2 cmH 2 O) and inspiratory oxygen fraction (FI,O 2 ; 61±18%). An end-inspiratory pause equal to 15% of the respiratory cycle was applied in all patients throughout the study. The study protocol was approved by the Institutional Review Board and informed consent was obtained from each patient or their next of kin.
Measurements
A fibreoptic pulmonary artery catheter was used for the measurement of pulmonary arterial pressure, pulmonary wedge pressure, central venous pressure, cardiac output and mixed venous oxygen saturation (Sv,O 2 ). Cardiac output was the mean of the values recorded after each of five thermodilution injections. Systemic arterial pressure was measured with a radial arterial catheter and arterial oxygen saturation (Sa,O 2 ) was monitored with a fibreoptic arterial catheter (U440 Oximetrix Opticath; Abbott, Chicago, IL, USA) inserted in a femoral artery. Cardiac frequency was measured from the electrocardiograph (ECG). In one patient, an intravascular blood gas monitoring system for pH, Pa,O 2 and arterial carbon dioxide tension (Pa,CO 2 ) (Paratrend 7; Biomedical Sensors, High Wycombe, UK) was used in conjunction with an arterial catheter in a femoral artery.
Airway flow, airway pressure and instantaneous CO 2 concentration between the Y-piece and endotracheal tube were measured. For this purpose, a screen pneumotachograph (PT-180; Jäger, Würzburg, Germany) and a Novametrix 1260 CO 2 analyser (Novametrix, Wallingford, CT, USA) were used. The dead space of the sensor head, which included the CO 2 analysis cuvette, was <15 mL. Airflow, airway pressure, instantaneous CO 2 concentration, arterial and mixed venous oxygen saturations were read simultaneously and continuously into a personal computer by means of an analogue/digital converter (DT2801-A; Data Translation, Marlboro, MA, USA) at a rate of 60 samples·s -1 ·channel -1 . An algorithm based on the CO 2 and flow signals detected the start of inspiration and expiration; this analysis enabled the automatic calculation of breath-by-breath lung function indices [19] . Digital recordings of systemic arterial pressure, pulmonary arterial pressure and central venous pressure were simultaneously obtained by means of a second DT2801-A analogue/digital converter at a rate of 250 samples·s -1 ·channel -1 . The sensors were calibrated before each study.
Haemoglobin, methaemoglobin, oxygen saturation and blood gases were measured in arterial and mixed venous blood samples. Standard formulae were used for the calculation of the cardiac index, systemic and pulmonary vascular resistance index, arterial and mixed venous oxygen content, venous admixture, oxygen delivery index and oxygen consumption index. The physiological dead space (Vd,phys) was calculated as follows [20] :
where VT,E is exhaled tidal volume, and PE,CO 2 is the mean expired partial CO 2 pressure in VT,E.
Measurements of total respiratory system mechanics were obtained in accordance with standard methods, as described elsewhere [21] . In brief, maximum inspiratory resistance, minimum inspiratory resistance and quasistatic compliance were measured by the constant flow, end-inspiratory occlusion method, and each value was the mean of the data obtained from analysis of three breaths. Total intrapulmonary PEEP (PEEPtot) was measured by the end-expiratory occlusion method, and each value was the average of the data obtained from three manoeuvres. The occlusion manoeuvres were maintained for 4 s.
Nitric oxide administration
Inhaled NO was administered from tanks containing NO in N 2 at a concentration of 1,000 ppm. Inhaled NO was administered by constant rate, sequential injection of the NO-N 2 mixture into the inspiratory limb of the ventilator external circuit, at 80 cm from the Y-piece [1] . Timed NO injection with the ventilator inflation phase was achieved by connection of the NO injection line to the nebulizer valve of the ventilator. The desired concentrations of inhaled NO in the inspiratory gases were achieved by a volumetric approach, which consisted of the regulation of the volume of the injected bolus of the NO-N 2 mixture on the basis of the values for tidal volume and the desired NO dose. The volume of injected bolus of the NO-N 2 mixture was measured with a fluid-filled, calibrated glass tube, which was connected to the NO injection line by means of a three-way stopcock. The NO-N 2 bolus injection represented an additional inspiratory volume which ranged 0.2-68 mL. The values for the injected volume of NO-N 2 were used to adjust the ventilator settings so as to maintain constant VT and FI,O 2 delivery to the patient. The adjustments in ventilator settings during NO inhalation consisted of a decrease in VT by 16±21 mL (range 0-70 mL) and in an increase in FI,O 2 by 1.8±2.5% (range 0-10%). During administration of each NO dose, delivered NO and NO 2 concentrations were checked at the beginning of administration and immediately after data collection, using an electrochemical analyser (Noxide M3; AIM, Corsica, Italy). The sampling port for NO and NO 2 analysis was sited on the inspiratory limb, close to the Y-piece. The Noxide M3 had a sampling rate of 500 mL·min -1 , and a nominal response time (t) which corresponded to a t90 of <60 s for both NO and NO 2 sensors. The Noxide M3 was calibrated before each study using a tank of nitrogen containing 80 ppm of NO and 10 ppm of NO 2 , as certified by the manufacturer (Messer Griesheim Italiana, Collegno, Italy). FI,O 2 was continuously monitored by a main-stream technique close to the port for NO and NO 2 sampling. Throughout the exposure to NO, the NO 2 levels measured in the inspiratory gases did not exceed 2 ppm in any of the patients.
Dose-response trials
Seven concentrations of inhaled NO were administered to each patient: 0.5, 1, 5, 10, 20, 50 and 100 ppm. In each patient, the different doses were administered in either an increasing or a decreasing sequence. The choice of the sequence was randomized.
Two sets of control measurements were obtained, one before and the other after the entire period of NO inhalation. All measurements were performed at steady state, as assessed from observation of trend values in pulmonary arterial pressure, systemic arterial pressure, lung function indices and oxygen saturation in arterial and mixed venous blood. A steady state was always achieved within 25 min in each condition. At this time, haemodynamic and respiratory measurements were performed. Furthermore, mixed venous and arterial blood samples were obtained.
Statistical analysis
All values are expressed as means±SD. In order to assess whether NO inhalation had a global effect, initial control values were compared with values obtained using graded NO concentrations. A contrast analysis was used for these comparisons. To assess whether NO inhalation had a dose-related effect, values obtained at the different concentrations of NO were compared using analysis of variance (ANOVA) for repeated measures. A p-value of <0.05 was considered significant for each of the two comparisons (contrast analysis and ANOVA). Calculations were made with the SuperANOVA statistical software (Abacus Concepts, Berkeley, CA, USA).
Results
As shown in figure 1 The average dose-response curves for inhaled NO for Sa,O 2 and methaemoglobin (MetHb) are illustrated in figure 4a and b, respectively. Inhaled NO significantly increased both Sa,O 2 (p<0.0001) and MetHb (p<0.005), compared with controls. The average response of Sa,O 2 did not differ significantly between the NO doses tested and was maximal at 1 ppm NO, where it reached a value of 96±1.4%. MetHb averaged 1.0±0.3% in the initial control condition, began to increase significantly with NO doses of 20 ppm and reached a maximum of 2.0±0.5% at 100 ppm NO (p<0.0001). The maximum individual MetHb value was 2.8%, at 100 ppm of inhaled NO.
As shown in table 2, mean systemic arterial pressure and cardiac index (CI) were not affected by NO inhalation. The oxygen delivery index (DO 2 ) and Sv,O 2 were significantly higher than controls at all doses of NO (p<0.05 and p <0.0001, respectively). Neither of these parameters differed significantly within the given range of NO doses. The oxygen consumption index (V 'O 2 ) was not affected by NO inhalation. Table 2 also reports the effects of NO inhalation on respiratory mechanics and ventilatory parameters. Tidal volume remained constant throughout the study. Minimum inspiratory resistance, maximum inspiratory resistance and quasistatic compliance of the respiratory system were not affected by NO inhalation.
On average, inhaled NO induced a slight, nonsignificant, decrease in both Pa,CO 2 and in Vd,phys. An evident effect of NO on Pa,CO 2 was detectable in patients 1, 5, 6 and 8, who all had an initial control Pa,CO 2 of >6.7 kPa (50 mmHg). Mean Pa,CO 2 for these patients was 8.0±1.2 kPa (60±9 mmHg) at initial control and 7.2±1.5 kPa (54±11 mmHg) at 100 ppm NO. Most of the decrease in Pa,CO 2 was obtained at NO doses in the 20-100 ppm range. In these four patients, Vd,phys, which was 257±88 mL at initial control, decreased at NO doses of 50 ppm (237±99 mL) and 100 ppm (233±89 mL). NO inhalation affected neither Pa,CO 2 , nor Vd,phys in patients 2, 3, 4 and 7, who all presented an initial control Pa,CO 2 level of <6.7 kPa (<50 mmHg). Figure 5 provides an example of the marked effect of inhaled NO on CO 2 elimination, in the form of the Pa,CO 2 dose-response curve for patient 8, in whom arterial pH and blood gases were continuously recorded. This patient's Pa,CO 2 variation profile indicates that the response was maximal in the 20-100 ppm NO range and that it began to diminish progressively at NO doses of <20 ppm.
Discussion
The present study extends previous investigations on the haemodynamic and respiratory dose-response curves of inhaled NO in ARDS patients. The results indicate that the NO doses required to reduce pulmonary hypertension and improve oxygenation were in the 0.5-5 ppm range and that high NO doses, i.e. 20-100 ppm, may improve CO 2 elimination in hypercapnic cases.
The present study provides further evidence that NO concentrations of 5 ppm may be sufficient to obtain maximal pulmonary vasodilation in ARDS patients. Similar findings have been reported in studies by PUYBASSET et al. [12] and ADATIA et al. [22] . NO doses of as little as 1-2 ppm have been shown to be sufficient for optimal treatment of pulmonary hypertension in ARDS patients [9] [10] [11] . In contrast with these, as well as with the present study, the optimal NO dose in terms of pulmonary vasodilation was found to be as high as 100 ppm by GERLACH et al. [13] . It is possible that the differences between the given findings are the result of a difference in the pati-ents studied. Most of the patients in the study by GERLACH et al. [13] were treated with extracorporeal membrane oxygenation, which may have affected the response to inhaled NO. The present study further confirms that low NO doses, i.e. in the 0.5-5 ppm range, progressively improve Pa,O 2 in ARDS patients [8] [9] [10] [11] [12] . In addition, the results indicate that the Pa,O 2 response to NO doses >5 ppm varies between patients. In half of the patients studied, the Pa,O 2 response was maximal at 5-10 ppm, while, at higher doses, there was a more or less pronounced tendency to decrease Pa,O 2 . In the remaining four patients, the Pa,O 2 response remained dose-dependent at up to 100 ppm. The various patterns in Pa,O 2 response observed in the present study support previous discordant findings on the doseresponse curves of NO for Pa,O 2 in ARDS patients. Some studies indicate that the effect of NO on Pa,O 2 reaches a plateau at 5 ppm or even lower doses [9] [10] [11] [12] . Other data show that high NO doses can even deteriorate the Pa,O 2 response [13] . Another profile of Pa,O 2 variation, namely, a dose-dependent increase in Pa,O 2 , has been reported to occur in the 0.1-150 ppm dose range [14] . Recently, a study by LUNDIN et al. [15] showed that, in patients with early ARDS, the NO dose required for optimal improvement in Pa,O 2 is on average 10 ppm, and varies substantially between individuals, ranging 0.1-100 ppm. The reasons for the variability in Pa,O 2 response to NO are still poorly understood [2, 10, 23] . In the present study, the two main profiles of Pa,O 2 response to NO depended neither on the aetiology of respiratory failure nor on the initial level of PVRI, Pa,O 2 , or Pa,CO 2 .
When oxygenation is analysed in terms of Ca,O 2 , this study indicated that 5 ppm was the lowest dose of inhaled NO that allowed the maximum improvement. Lack of further improvement in Ca,O 2 for higher doses was due to a combination of factors. Firstly, in 50% of the patients, the Pa,O 2 response to doses >5 ppm flattened or decreased. Secondly at 5 ppm inhaled NO, the average Pa,O 2 was 19.2±11.7 kPa (144±88 mmHg), the minimum observed Pa,O 2 was 11.3 kPa (85 mmHg), and, hence, the theoretical Sa,O 2 was nearly maximal in all patients. Finally, at doses of inhaled NO Š20 ppm, any possible increase in Ca,O 2 due to an increase in Pa,O 2 was offset by the increase in MetHb, the latter resulting in a reduction in the haemoglobin available for O 2 binding.
The amount of MetHb formation from NO depends on the concentration of inhaled NO and the duration of NO inhalation [24, 25] . Inhalation of NO doses of <100 ppm, even for long periods, carries little risk of methaemoglobinaemia (as defined by a MetHb >6%) in adult patients [26] . In agreement with these data, the present study found the Calculation of DO 2 allows the evaluation of the net effect of inhaled NO on the total supply of oxygen. In the present study DO 2 showed a slight, dose-independent increase with NO inhalation. Potentially, inhaled NO can increase DO 2 by two mechanisms: through increases in Ca,O 2 and through increases in CI. Clinically relevant increases in CI are induced by inhaled NO only when right ventricular function is severely impaired, which is a rare event in ARDS patients [27, 28] . The present study further confirms that normally, in ARDS patients, inhaled NO does not significantly affect CI, while the benefit of inhaled NO on DO 2 depends entirely on increased Ca,O 2 . The ARDS patients in the present study responded to the NO-induced increase in DO 2 with a lack of change in V 'O 2 , and with an increase in Sv,O 2 . These findings indicate a lack of dependency of V 'O 2 on DO 2 . In other words, adequate tissue oxygenation was achieved even without inhaled NO administration.
Studies in the literature indicate that, in ARDS patients, inhaled NO may improve gas exchange not only by reducing hypoxaemia, but also by improving CO 2 elimination [1, 9, 12] . NO-induced improvement in CO 2 elimination can be explained by a reduction in alveolar dead space, which in turn is caused by increased perfusion of ventilated lung areas. In the present study, inhaled NO decreased Pa,CO 2 only in patients with initial Pa,CO 2 values >6.7 kPa (50 mmHg). The results suggest that high NO doses (Š20 ppm) may be required to obtain a substantial improvement in CO 2 elimination and that this improvement is to be expected, especially when the Pa,CO 2 level is pathologically increased. Although of potential benefit for CO 2 elimination, the administration of high NO doses increases both direct NO toxicity and the oxidation of NO to NO 2 , the latter being far more toxic than NO. The rate of NO 2 formation depends on both the oxygen concentration, which is usually high in ARDS patients and the square of NO concentration. Hence, the use of high NO concentrations for the sole purpose of improving CO 2 elimination should be considered with caution. The present study demonstrates that NO inhalation over the 0.5-100 ppm dose range does not affect respiratory mechanics in ARDS patients. In agreement with these results, PUYBASSET et al. [29] did not find changes in airway resistance in the 10-80 ppm NO dose range, and BIGATELLO et al. [2] did not observe changes in respiratory compliance in the 5-40 ppm NO dose range. These results support the hypothesis that the NO-induced beneficial effects on the ventilation-perfusion ratio are not related to a reduction in hypoventilated regions of the lung.
In conclusion, this study shows that the optimal dose of nitric oxide for the treatment both of pulmonary hypertension and of hypoxaemia in patients with acute respiratory distress syndrome is approximately 5 ppm. Presently, there is no evidence of toxicity for nitric oxide doses of up to 5 ppm. Administration of higher doses of nitric oxide may further improve arterial oxygen tension, but is unlikely to provide additional benefits in terms of arterial oxygen content. High doses of nitric oxide (Š20 ppm) may be required to obtain an improvement in carbon dioxide elimination, but the risk-to-benefit ratio must be evaluated. 
